You searched for "Diabetic"
Diabetes macular oedema in pregnancy self-resolving postpartum
*Equally contributing co-first authors. Diabetic macular oedema (DMO) is a common clinical presentation to ophthalmology clinics. Ample evidence exists for management of DMO in non-pregnant patients. However, there is a paucity of evidence on the optimal management of DMO in...100 years of insulin
*Joint first authors The centenary of the discovery of insulin is a time to celebrate one of the most significant scientific discoveries of the 20th century. Background Before 1923, Type 1 diabetes mellitus [T1DM] resulted in death from severe ketoacidosis...Cataract incidence rates in patients from the UK suffering with diabetes mellitus
The authors summarise the main findings from a recent study which investigated the incidence rates of cataract in patients with or without diabetes mellitus (DM). Background to the study Worldwide, the World Health Organization (WHO) estimates that 253 million people...Don’t ignore the black lesion! It might be mucormycosis
Keeping mucormycosis infection in the foreground of your differential diagnosis, especially in those more vulnerable patients, will help save their lives if recognised and managed appropriately. Mucormycosis is a fulminant infection caused by the fungi of the family Mucoraceae. It...
Visual acuity outcomes after cataract surgery in type 2 diabetes (NIDDM): the action to control cardiovascular risk in diabetes (ACCORD) study
This is a retrospective case-control study of 1136 eyes enrolled in the 784 ACCORD patients receiving cataract surgery between 2001-2014. 362 / 1136 eyes had gradable fundus photography for diabetic retinopathy (DR). Seven hundred and sixty-two eyes (67.1%) achieved 20...Moorfields Education: Implementing a non-medical intravitreal injection service (19 May)
This course is for clinicians working in an ophthalmic or medical retina setting, focusing on the treatment of age-related macular degeneration, retinal vein occlusion and diabetic oedema. .
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Prognostic information for PRP-naive patients
The Diabetic Retinopathy Study group demonstrated that pan retinal laser photocoagulation (PRP) reduces severe vision loss by up to 50% in cases of proliferative diabetic retinopathy (PDR). The authors of this current study aimed to provide information for laser naive...
